171 related articles for article (PubMed ID: 34435997)
1. Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology.
Alsalih A; Dam A; Lindberg P; Truedsson A
Dent J (Basel); 2021 Jul; 9(8):. PubMed ID: 34435997
[TBL] [Abstract][Full Text] [Related]
2. A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw.
Bullock G; Miller CA; McKechnie A; Hearnden V
Front Oral Health; 2021; 2():822411. PubMed ID: 35224540
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
[TBL] [Abstract][Full Text] [Related]
4. Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.
Hokugo A; Kanayama K; Sun S; Morinaga K; Sun Y; Wu Q; Sasaki H; Okawa H; Evans C; Ebetino FH; Lundy MW; Sadrerafi K; McKenna CE; Nishimura I
Bone; 2019 Jun; 123():115-128. PubMed ID: 30926440
[TBL] [Abstract][Full Text] [Related]
5. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.
Kuroshima S; Sasaki M; Murata H; Sawase T
Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407
[TBL] [Abstract][Full Text] [Related]
6. Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model.
Saracino S; Canuto RA; Maggiora M; Oraldi M; Scoletta M; Ciuffreda L; Vandone AM; Carossa S; Mozzati M; Muzio G
J Oral Pathol Med; 2012 Nov; 41(10):788-92. PubMed ID: 22650360
[TBL] [Abstract][Full Text] [Related]
7. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis.
Limones A; Sáez-Alcaide LM; Díaz-Parreño SA; Helm A; Bornstein MM; Molinero-Mourelle P
Med Oral Patol Oral Cir Bucal; 2020 May; 25(3):e326-e336. PubMed ID: 32271321
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database.
Hasegawa S; Ikesue H; Satake R; Inoue M; Yoshida Y; Tanaka M; Matsumoto K; Wakabayashi W; Oura K; Muroi N; Hashida T; Iguchi K; Nakamura M
Drugs Real World Outcomes; 2022 Dec; 9(4):659-665. PubMed ID: 35933498
[TBL] [Abstract][Full Text] [Related]
9. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
11. Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid.
Ciobanu GA; Mogoantă L; Popescu SM; Ionescu M; Munteanu CM; Staicu IE; Mercuț R; Georgescu CC; Scrieciu M; Vlad D; Camen A
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762651
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
Barba-Recreo P; Del Castillo Pardo de Vera JL; García-Arranz M; Yébenes L; Burgueño M
J Craniomaxillofac Surg; 2014 Sep; 42(6):744-50. PubMed ID: 24342733
[TBL] [Abstract][Full Text] [Related]
13. Endothelial progenitors increase vascularization and improve fibroblasts function that prevent medication-related osteonecrosis of the jaw.
Doppelt O; Cohen G; Tamari T; Elimelech R; Sabbah N; Zigdon-Giladi H
Oral Dis; 2020 Oct; 26(7):1523-1531. PubMed ID: 32400918
[TBL] [Abstract][Full Text] [Related]
14. Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy.
Tamari T; Elimelech R; Cohen G; Cohen T; Doppelt O; Eskander-Hashoul L; Zigdon-Giladi H
Sci Rep; 2019 Dec; 9(1):18896. PubMed ID: 31827217
[TBL] [Abstract][Full Text] [Related]
15. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
16. Effects of the prevention of medication-related osteonecrosis of the jaw by local administration of a dental pulp stem cell-conditioned medium to the rat tooth extraction socket.
Kushiro H; Takahashi H; Tanaka A
Odontology; 2021 Oct; 109(4):836-844. PubMed ID: 33907964
[TBL] [Abstract][Full Text] [Related]
17. Gingival fibroblasts and medication-related osteonecrosis of the jaw: Results by real-time and wound healing in vitro assays.
Yuan A; Munz A; Reinert S; Hoefert S
J Craniomaxillofac Surg; 2019 Sep; 47(9):1464-1474. PubMed ID: 31327558
[TBL] [Abstract][Full Text] [Related]
18. Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats.
Bolette A; Lecloux G; Rompen E; Albert A; Kerckhofs G; Lambert F
J Craniomaxillofac Surg; 2019 Feb; 47(2):349-356. PubMed ID: 30595476
[TBL] [Abstract][Full Text] [Related]
19. Experimental model of osteonecrosis of the jaw in rats treated with zoledronic acid.
Kolpakova ME; Zubarevа AA; Artamonova TD; Lisovskaya EK; Chefu SG; Yagmurov OD; Yaremenko AI; Vlasov TD
Br J Oral Maxillofac Surg; 2017 Feb; 55(2):156-159. PubMed ID: 27780611
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Reverses the Inhibitory Effects of the Bisphosphonate, Zoledronic Acid, on Human Oral Keratinocytes and Human Vascular Endothelial Cells In Vitro via the Epidermal Growth Factor Receptor (EGFR)/Akt/Phosphoinositide 3-Kinase (PI3K) Signaling Pathway.
Wang Q; Liu J; Guo T; Liu D; Pan J
Med Sci Monit; 2019 Jan; 25():700-710. PubMed ID: 30675875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
